Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: muscarinic receptor agonists and antagonists - ACADIA/Sepracor

Next Previous
X
Search
Drug Profile

Research programme: muscarinic receptor agonists and antagonists - ACADIA/Sepracor

Alternative Names: 108LM39-36; AC 90987; AC-260584

Latest Information Update: 26 Mar 2008

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ACADIA Pharmaceuticals; Sepracor
  • Class
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued CNS disorders; Cognition disorders; Neuropathic pain; Psychotic disorders; Schizophrenia

Most Recent Events

  • 21 Jan 2005 ACADIA and Sepracor entered into an agreement to jointly develop therapeutic agents for the treatment of CNS disorders
  • 04 Aug 2004 Preclinical trials in Schizophrenia in USA (unspecified route)
  • 07 Apr 2003 Data presented at the 225th American Chemical Society Meeting (225th-ACS) have been added to the adverse events section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top